Biogen

Biogen beat revenue and earnings per share in the third quarter, confirming the stock's upward movement. Leqembi revenue, at $202 million, was just below expectations, while Spinraza and Syfovre, bolstered by the Apellis acquisition, drove the results. Several analysts then substantially increased their price targets (Argus 280, JPMorgan 325, Goldman 295, Jefferies 290) and mostly recommend buy. With an expected P/E ratio of 15 for 2027, the stock still does not appear expensive according to the report. » More on deraktionaer.de

Biogen reported Q3 revenue up 11% to $2.80 billion; the growth division contributed $1.26 billion (+49%), with the acquired Apellis business delivering its first full quarter. Adjusted EPS fell to $2.62 but exceeded market expectations, as did revenue. For 2026, Biogen raised the lower end of its earnings target to $12.20 (upper end $13.00) and expects adjusted earnings of $15.95–16.75, as well as mid-single-digit revenue growth over the medium term. The stock reached a new two-year high. » More on deraktionaer.de

JPMorgan raises Biogen from neutral to overweight and increases the price target to $300, supported by expected study data for candidates such as felzartamab and litifilimab. Biogen remains profitable but is weighed down by transaction costs, acquisition dilution and investments; net debt was about $6.8 billion at the end of June. Crucial for the share performance are upcoming phase‑3 readouts through mid‑2027, while BioNTech’s valuation depends more on data and its cash position. » More on finanzen.net

US markets showed a mixed picture before the start of earnings season: the Nasdaq 100 fell, the S&P 500 remained nearly unchanged and the Dow rose. JPMorgan upgraded Biogen, citing an increasingly promising development in 2027 and improved long-term growth prospects. The news pushed Biogen shares up 2.4 percent. » More on deraktionaer.de

JPMorgan upgraded Biogen from “neutral” to “overweight” and raised the price target from $210 to $300, citing an improved long‑term growth outlook and a promising pipeline. Key drivers include expected study data in 2026–2027 for an anti‑Tau Alzheimer drug, litifilimab for systemic and cutaneous lupus, and felzartamab, which could have a market potential of more than $2 billion. The news supported the stock’s recent premarket gain and reinforces JPMorgan’s view of a high probability of success for Leqembi. » More on deraktionaer.de